Spectrum to Develop Rituximab Biosimilar

9 January 2011 (Last Updated January 9th, 2011 18:30)

Spectrum Pharmaceuticals has signed a letter of agreement with Viropro to develop a biosimilar version of Genentech / Roche's monoclonal antibody drug rituximab. The deal seeks to capitalise on patent expirations for Rituximab, which achieved worldwide sales of about $5.6 billion in 20

Spectrum Pharmaceuticals has signed a letter of agreement with Viropro to develop a biosimilar version of Genentech / Roche's monoclonal antibody drug rituximab.

The deal seeks to capitalise on patent expirations for Rituximab, which achieved worldwide sales of about $5.6 billion in 2009.

Biosimilars, also known as follow-on biologics, are officially-approved versions of biopharmaceutical products made by a different company following patent and exclusivity expiry of the innovator product.